Nuveen Asset Management’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $1.26M | Sell |
79,485
-181,863
| -70% | -$2.88M | ﹤0.01% | 2604 |
|
|
2024
Q3 | $15.2M | Buy |
261,348
+153,568
| +142% | +$8.92M | ﹤0.01% | 1363 |
|
|
2024
Q2 | $4.93M | Buy |
107,780
+6,541
| +6% | +$299K | ﹤0.01% | 1962 |
|
|
2024
Q1 | $6.7M | Buy |
101,239
+25,643
| +34% | +$1.7M | ﹤0.01% | 1826 |
|
|
2023
Q4 | $3.01M | Buy |
75,596
+4,578
| +6% | +$182K | ﹤0.01% | 2224 |
|
|
2023
Q3 | $2.26M | Buy |
71,018
+19,359
| +37% | +$617K | ﹤0.01% | 2248 |
|
|
2023
Q2 | $2.08M | Sell |
51,659
-15,510
| -23% | -$623K | ﹤0.01% | 2322 |
|
|
2023
Q1 | $2.87M | Buy |
67,169
+1,830
| +3% | +$78.1K | ﹤0.01% | 2186 |
|
|
2022
Q4 | $3.14M | Buy |
65,339
+646
| +1% | +$31K | ﹤0.01% | 2173 |
|
|
2022
Q3 | $2.43M | Buy |
64,693
+1,753
| +3% | +$65.9K | ﹤0.01% | 2295 |
|
|
2022
Q2 | $1.74M | Buy |
62,940
+2,445
| +4% | +$67.6K | ﹤0.01% | 2505 |
|
|
2022
Q1 | $3.08M | Sell |
60,495
-2,982
| -5% | -$152K | ﹤0.01% | 2303 |
|
|
2021
Q4 | $2.97M | Sell |
63,477
-4,625
| -7% | -$217K | ﹤0.01% | 2372 |
|
|
2021
Q3 | $2.09M | Sell |
68,102
-47,363
| -41% | -$1.46M | ﹤0.01% | 2653 |
|
|
2021
Q2 | $4.9M | Sell |
115,465
-8,822
| -7% | -$375K | ﹤0.01% | 2257 |
|
|
2021
Q1 | $7.65M | Buy |
124,287
+29,275
| +31% | +$1.8M | ﹤0.01% | 1941 |
|
|
2020
Q4 | $6.7M | Buy |
95,012
+67,928
| +251% | +$4.79M | ﹤0.01% | 1920 |
|
|
2020
Q3 | $1.05M | Buy |
27,084
+114
| +0.4% | +$4.4K | ﹤0.01% | 2670 |
|
|
2020
Q2 | $1.01M | Buy |
+26,970
| New | +$1.01M | ﹤0.01% | 2619 |
|